Stockhub

Aptahem AB

Revision as of 04:46, 16 August 2022 by >Paris (Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Aptahem AB (publ), a biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in pre-clinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various consultants and contract research laboratories, including The Nencki Institute of E...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Summary[1] edit edit source

Aptahem AB (publ), a biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in pre-clinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various consultants and contract research laboratories, including The Nencki Institute of Experimental Biology, BioSpring, Red Glead Discovery, SmiLe Incubator, Truly Translational Sweden AB, Axolabs, Accelera, PKxpert AB, Hooke Laboratories; Cardiovascular Research Centre; and Ã-rebro University. Aptahem AB (publ) was founded in 2014 and is based in Malmö, Sweden.

References and notes edit edit source

  1. ↑ Source: Yahoo Finance.
Retrieved from "https://stockhub.co/index.php?title=Aptahem_AB&oldid=52296"